Centre caps trade margins at 30% for 137 non-scheduled cancer drugs

The central government has announced a decisive intervention in cancer drug pricing, imposing a maximum trade margin cap of 30% on 137 non-scheduled cancer medications. The move is intended to contain escalating costs for patients seeking treatment while maintaining the viability of the pharmaceutical distribution chain.

Under the new regulatory framework, the capped trade margins—comprising all intermediary markups from manufacturer to retailer—will apply uniformly across the identified cancer drugs. The measure represents a significant tightening of price controls in a therapeutic category where medication costs have been a persistent concern for patients and healthcare providers alike.

Implementation of the price controls is slated to commence on November 9, 2026, providing stakeholders with a transitional period to align their operations with the revised margins. State drug controllers will assume primary responsibility for monitoring compliance with the new pricing norms, ensuring that retailers and distributors adhere to the stipulated cap.

The decision reflects the government's broader commitment to regulating pharmaceutical pricing in critical therapeutic areas. By capping trade margins rather than fixing absolute prices, authorities aim to balance affordability for patients with incentives for the supply chain to continue distributing these essential medications across the country.